Soligenix corporate update includes nda plans for hybryte(tm)

New york, new york--(newsfile corp. - january 12, 2022) - pcg digital -- soligenix, inc. (nasdaq: sngx), a us-based late-stage biopharmaceutical company, issued a corporate update this week with good news for their shareholders. despite supply-chain delays in receiving the active pharmaceutical ingredient for sgx301, aka hybryte™, the company is still on track to file a new drug application with the fda in the latter half of 2022. hybryte™ is an early-stage treatment for cutaneous...
SNGX Ratings Summary
SNGX Quant Ranking